Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
509
mi
from 43215
Olive Branch, MS
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
509
mi
from 43215
Olive Branch, MS
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
1538
mi
from 43215
Butte, MT
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
1538
mi
from 43215
Butte, MT
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
428
mi
from 43215
Berlin, NJ
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
428
mi
from 43215
Berlin, NJ
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
321
mi
from 43215
Greensboro, NC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
321
mi
from 43215
Greensboro, NC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
304
mi
from 43215
Hickory, NC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
304
mi
from 43215
Hickory, NC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
371
mi
from 43215
Raleigh, NC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
6
mi
from 43215
Columbus, OH
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
63
mi
from 43215
Kettering, OH
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
63
mi
from 43215
Kettering, OH
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
134
mi
from 43215
Lyndhurst, OH
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
134
mi
from 43215
Lyndhurst, OH
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
43
mi
from 43215
Marion, OH
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
43
mi
from 43215
Marion, OH
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
849
mi
from 43215
Oklahoma City, OK
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
2057
mi
from 43215
Eugene, OR
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
2057
mi
from 43215
Eugene, OR
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
524
mi
from 43215
Mount Pleasant, SC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
524
mi
from 43215
Mount Pleasant, SC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
363
mi
from 43215
Simpsonville, SC
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
363
mi
from 43215
Simpsonville, SC
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
239
mi
from 43215
Bristol, TN
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
239
mi
from 43215
Bristol, TN
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
1069
mi
from 43215
Austin, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
1174
mi
from 43215
Corpus Christi, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
1174
mi
from 43215
Corpus Christi, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
944
mi
from 43215
Ft. Worth, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
944
mi
from 43215
Ft. Worth, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
1008
mi
from 43215
Katy, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
1008
mi
from 43215
Katy, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
1144
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated:  9/8/2015
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
Status: Enrolling
Updated: 9/8/2015
Clinical Research Facility
341
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Alabama at Birmingham
493
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Arizona Pulmonary Specialists
1661
mi
from 43215
Pheonix, AZ
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Arizona Pulmonary Specialists
1661
mi
from 43215
Pheonix, AZ
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
GLVA Healthcare Center
mi
from 43215
Los Angeles, CA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
GLVA Healthcare Center
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of California, San Diego
1926
mi
from 43215
San Diego, CA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of California, San Diego
1926
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Santa Barbara Cottage Hospital
2042
mi
from 43215
Santa Barbara, CA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Santa Barbara Cottage Hospital
2042
mi
from 43215
Santa Barbara, CA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
LIU Center for Pulmonary Hypertension
1983
mi
from 43215
Torrance, CA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
LIU Center for Pulmonary Hypertension
1983
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Colorado Health Sciences Center
1159
mi
from 43215
Denver, CO
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Colorado Health Sciences Center
1159
mi
from 43215
Denver, CO
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Mayo Clinic, Jacksonville
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease
436
mi
from 43215
Atlanta, GA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease
436
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Pulmonary & Critical Care of Atlanta
426
mi
from 43215
Atlanta, GA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Pulmonary & Critical Care of Atlanta
426
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Southeastern Lung Care PC
433
mi
from 43215
Decatur, GA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Southeastern Lung Care PC
433
mi
from 43215
Decatur, GA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
The University of Chicago Hospitals
270
mi
from 43215
Chicago, IL
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
The University of Chicago Hospitals
270
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Iowa
461
mi
from 43215
Iowa City, IA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Iowa
461
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Kansas Medical Center
627
mi
from 43215
Kansas City, KA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Kentuckiana Pulmonary Associate, PLLC
188
mi
from 43215
Louisville, KY
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Kentuckiana Pulmonary Associate, PLLC
188
mi
from 43215
Louisville, KY
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Medical Center of Louisiana - New Orleans
797
mi
from 43215
New Orleans, LA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Medical Center of Louisiana - New Orleans
797
mi
from 43215
New Orleans, LA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Maine Medical Center
704
mi
from 43215
Portland, ME
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Maine Medical Center
704
mi
from 43215
Portland, ME
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Maryland School of Medicine
343
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Boston University School of Medicine
642
mi
from 43215
Boston, MA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Boston University School of Medicine
642
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Pulmonary/Critical Care Division/Tufts New England Medical Center
643
mi
from 43215
Boston, MA
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Pulmonary/Critical Care Division/Tufts New England Medical Center
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Michigan
164
mi
from 43215
Ann Arbor, MI
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Washington University School of Medicine
397
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of NJ - Robert Wood Johnson Medical School
453
mi
from 43215
New Brunswick, NJ
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of NJ - Robert Wood Johnson Medical School
453
mi
from 43215
New Brunswick, NJ
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Columbia University Medical Center, Pediatric Cardiology
481
mi
from 43215
New York, NY
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Columbia University Medical Center, Pediatric Cardiology
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
Duke Univ Med Ctr
352
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated:  9/10/2015
University of Cincinnati Ohio Heart Health Center
99
mi
from 43215
Cincinnati, OH
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
Status: Enrolling
Updated: 9/10/2015
University of Cincinnati Ohio Heart Health Center
99
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials